RAG 17
Alternative Names: RAG-17Latest Information Update: 22 May 2024
At a glance
- Originator Ractigen Therapeutics
- Class Drug conjugates; Oligonucleotides; Small interfering RNA
- Mechanism of Action RNA interference; Superoxide dismutase 1 expression inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase 0 Amyotrophic lateral sclerosis
Most Recent Events
- 15 May 2024 The Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) approves the investigational new drug (IND) application for phase I clinical trial in Amyotrophic lateral sclerosis (ALS)
- 22 May 2023 Phase-0 for Amyotrophic lateral sclerosis in China (Intrathecal) (NCT05903690)
- 08 Mar 2023 RAG 17 is available for licensing as of 08 Mar 2023. https://www.ractigen.com/industrial-partnerships/ (Ractigen Therapeutics website, February 2023)